

# Michel Komajda

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3837280/michel-komajda-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

239  
papers

32,266  
citations

80  
h-index

178  
g-index

268  
ext. papers

38,469  
ext. citations

9.8  
avg. IF

6.47  
L-index

#	Paper	IF	Citations
239	Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23. <i>European Heart Journal</i> , <b>2021</b> , 42, 2000-2011	9.5	14
238	Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. <i>Circulation</i> , <b>2021</b> , 143, 326-336	16.7	74
237	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 117-128	59.2	408
236	Asymptomatic left ventricular dysfunction in patients with type 2 diabetes free of cardiovascular disease and its relationship with clinical characteristics: The DIACAR cohort study. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 434-443	6.7	1
235	Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY international registry. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 861-871	3.7	8
234	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial. <i>Annals of Internal Medicine</i> , <b>2021</b> , 174, 1065-1072	8	6
233	Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. <i>Circulation</i> , <b>2021</b> , 144, 1284-1294	16.7	30
232	Comparison of Outcome Adjudication by Investigators and by a Central End Point Committee in Heart Failure Trials: Experience of the SHIFT Heart Failure Study. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e006720	7.6	11
231	European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 196-213	12.3	85
230	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , <b>2020</b> , 41, 255-323	9.5	1360
229	Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 418-427	7.9	10
228	Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 921-929	12.3	53
227	Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1270-1278	12.3	73
226	Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 601-612	15.1	40
225	Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 974-984	12.3	30
224	Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1279-1287	12.3	133
223	Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. <i>ESC Heart Failure</i> , <b>2019</b> , 6, 1199-1207	3.7	7

222	Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , <b>2019</b> , 12, e006539	7.6	36
221	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 853-872	12.3	264
220	The chronic ischaemic cardiovascular disease ESC Pilot Registry: Results of the six-month follow-up. <i>European Journal of Preventive Cardiology</i> , <b>2018</b> , 25, 377-387	3.9	8
219	Role of ivabradine in management of stable angina in patients with different clinical profiles. <i>Open Heart</i> , <b>2018</b> , 5, e000725	3	5
218	Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 373-381	12.3	24
217	Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1315-1322	12.3	62
216	Diabète et insuffisance cardiaque : données épidémiologiques et implications thérapeutiques.. <i>Bulletin De L'Académie Nationale De Médecine</i> , <b>2018</b> , 202, 909-917	0.1	0
215	Efficacité et effets indésirables des statines: données et politiques. <i>Bulletin De L'Académie Nationale De Médecine</i> , <b>2018</b> , 202, 817-835	0.1	
214	Pregnancy in women with a cardiomyopathy: Outcomes and predictors from a retrospective cohort. <i>Archives of Cardiovascular Diseases</i> , <b>2018</b> , 111, 199-209	2.7	20
213	Patient journey in decompensated heart failure: An analysis in departments of cardiology and geriatrics in the Greater Paris University Hospitals. <i>Archives of Cardiovascular Diseases</i> , <b>2017</b> , 110, 42-50	2.7	10
212	Comments on meta-analysis of ivabradine as adjuvant treatment for chronic heart failure by Mizzaci et al. <i>International Journal of Cardiology</i> , <b>2017</b> , 239, 2	3.2	
211	Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT-HF randomized phase 2 trial. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 1534-1541	12.3	50
210	Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 1495-1503	12.3	111
209	Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 1414-1423	12.3	126
208	Heart rate and its reduction in chronic heart failure and beyond. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 1230-1241	12.3	24
207	Brain natriuretic peptide usefulness in very elderly dyspnoeic patients: the BED study. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 540-548	12.3	16
206	Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). <i>Circulation</i> , <b>2017</b> , 135, 724-735	16.7	100
205	Quality of Physician Adherence to Guideline Recommendations for Life-saving Treatment in Heart Failure: an International Survey. <i>Cardiac Failure Review</i> , <b>2017</b> , 3, 130-133	4.2	9

204	Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. <i>European Heart Journal</i> , <b>2017</b> , 38, 742-750	9.5	25
203	Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes. <i>Cardiovascular Drugs and Therapy</i> , <b>2017</b> , 31, 233-246	3.9	72
202	Financial impact of ivabradine on reducing heart failure penalties under the Hospital Readmission Reduction Program. <i>Current Medical Research and Opinion</i> , <b>2017</b> , 33, 185-191	2.5	2
201	Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , <b>2017</b> , 23, 20-28	3.3	20
200	Exome-wide association study reveals novel susceptibility genes to sporadic dilated cardiomyopathy. <i>PLoS ONE</i> , <b>2017</b> , 12, e0172995	3.7	66
199	Cardiomyopathie Diabétique: une entité spécifique?. <i>Bulletin De L'Académie Nationale De Médecine</i> , <b>2017</b> , 201, 325-337	0.1	1
198	EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT). <i>European Heart Journal</i> , <b>2016</b> , 37, 152-60	9.5	21
197	Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial. <i>European Heart Journal</i> , <b>2016</b> , 37, 365-74	9.5	99
196	Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF Trial). <i>American Journal of Cardiology</i> , <b>2016</b> , 117, 1771-8	3	23
195	Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 514-22	12.3	118
194	Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. <i>European Heart Journal</i> , <b>2016</b> , 37, 1850-8	9.5	473
193	The year in cardiology 2015: heart failure. <i>European Heart Journal</i> , <b>2016</b> , 37, 437-41	9.5	1
192	How can the European Society of Cardiology ensure compliance with ethical standards?. <i>European Heart Journal</i> , <b>2016</b> , 37, 741-4	9.5	3
191	Maladies rares, le modèle français. <i>Bulletin De L'Académie Nationale De Médecine</i> , <b>2016</b> , 200, 979-991	0.1	
190	Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2016</b> , 22, 1064-71	1.9	1
189	Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 328-36	12.3	62
188	Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 672-83	12.3	15
187	Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 1021-31	12.3	13

186	Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 1182-9	12.3	30
185	Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 169-76	12.3	25
184	Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 518-26	12.3	43
183	Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 268-9	7.9	3
182	Involvement of BAG3 and HSPB7 loci in various etiologies of systolic heart failure: Results of a European collaboration assembling more than 2000 patients. <i>International Journal of Cardiology</i> , <b>2015</b> , 189, 105-7	3.2	18
181	The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction). <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 429-441	7.9	48
180	A 22-Year Follow-up Study of Long-term Cardiac Outcome and Predictors of Survival in Friedreich Ataxia. <i>JAMA Neurology</i> , <b>2015</b> , 72, 1334-41	17.2	45
179	Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial. <i>Circulation: Heart Failure</i> , <b>2015</b> , 8, 717-24	7.6	15
178	Unresolved issues in the management of chronic stable angina. <i>International Journal of Cardiology</i> , <b>2015</b> , 201, 200-7	3.2	19
177	Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 478-486	7.9	17
176	Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial). <i>American Journal of Cardiology</i> , <b>2015</b> , 116, 1890-7	3	48
175	International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. <i>Circulation</i> , <b>2015</b> , 131, 43-53	16.7	58
174	Atlas of the clinical genetics of human dilated cardiomyopathy. <i>European Heart Journal</i> , <b>2015</b> , 36, 1123-35	3.9	334
173	Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. <i>European Heart Journal</i> , <b>2015</b> , 36, 657-68	9.5	591
172	Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 809-17	12.3	45
171	Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 1294-301	12.3	51
170	Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 925-35	12.3	120
169	Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the MAGGIC meta-analysis. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 1182-91	12.3	37

168	Top ten risk factors for morbidity and mortality in patients with chronic systolic heart failure and elevated heart rate: The SHIFT Risk Model. <i>International Journal of Cardiology</i> , <b>2015</b> , 184, 163-169	3.2	34
167	Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). <i>American Journal of Cardiology</i> , <b>2014</b> , 113, 497-503	3	37
166	Heart failure with preserved ejection fraction: a clinical dilemma. <i>European Heart Journal</i> , <b>2014</b> , 35, 1022-32	9.3	136
165	A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , <b>2014</b> , 16, 1175-82	12.3	53
164	Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). <i>European Journal of Heart Failure</i> , <b>2014</b> , 16, 778-87	12.3	60
163	Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 1106-13	15.1	48
162	The atrial fibrillation ablation pilot study: a European Survey on Methodology and results of catheter ablation for atrial fibrillation conducted by the European Heart Rhythm Association. <i>European Heart Journal</i> , <b>2014</b> , 35, 1466-78	9.5	141
161	Prevalence of memory disorders in ambulatory patients aged $\geq$ 70 years with chronic heart failure (from the EFICARE study). <i>American Journal of Cardiology</i> , <b>2014</b> , 113, 1205-10	3	27
160	Pretest probability of a normal echocardiography: validation of a simple and practical algorithm for routine use. <i>Archives of Cardiovascular Diseases</i> , <b>2014</b> , 107, 105-11	2.7	1
159	A genome-wide association study identifies 6p21 as novel risk locus for dilated cardiomyopathy. <i>European Heart Journal</i> , <b>2014</b> , 35, 1069-77	9.5	97
158	Left atrial volume predicts abnormal exercise left ventricular filling pressure. <i>European Journal of Heart Failure</i> , <b>2014</b> , 16, 1089-95	12.3	15
157	Below-knee arterial calcification in type 2 diabetes: association with receptor activator of nuclear factor B ligand, osteoprotegerin, and neuropathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 99, 4250-8	5.6	15
156	Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT. <i>European Journal of Heart Failure</i> , <b>2014</b> , 16, 810-6	12.3	51
155	History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. <i>Circulation: Heart Failure</i> , <b>2014</b> , 7, 960-6	7.6	28
154	The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. <i>European Journal of Heart Failure</i> , <b>2014</b> , 16, 426-34	12.3	31
153	Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. <i>ESC Heart Failure</i> , <b>2014</b> , 1, 52-58	3.7	31
152	Sustainable Development Goals and the future of cardiovascular health: a statement from the Global Cardiovascular Disease Taskforce. <i>Journal of the American Heart Association</i> , <b>2014</b> , 3, e000504	6	21
151	Sustainable development goals and the future of cardiovascular health: a statement from the Global Cardiovascular Disease Taskforce. <i>Global Heart</i> , <b>2014</b> , 9, 273-4	2.9	13

150	Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency <b>2014</b> , 1, 52		1
149	Sustainable Development Goals and the future of cardiovascular health. A statement from the Global Cardiovascular Disease Taskforce. <i>European Heart Journal</i> , <b>2014</b> , 35, 3238-9	9.5	3
148	The wealth of nations and the dissemination of cardiovascular research. <i>International Journal of Cardiology</i> , <b>2013</b> , 169, 190-5	3.2	6
147	Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. <i>Heart Failure Reviews</i> , <b>2013</b> , 18, 107-22	5	39
146	Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. <i>European Heart Journal</i> , <b>2013</b> , 34, 2149-57	9.5	184
145	Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, 1977-1985	15.1	90
144	Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 79-84	12.3	21
143	Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 1296-303	12.3	51
142	A novel genetic variant in the transcription factor Islet-1 exerts gain of function on myocyte enhancer factor 2C promoter activity. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 267-76	12.3	17
141	Risk following hospitalization in stable chronic systolic heart failure. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 885-91	12.3	40
140	Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people. <i>Archives of Cardiovascular Diseases</i> , <b>2013</b> , 106, 303-23	2.7	40
139	Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. <i>European Heart Journal</i> , <b>2013</b> , 34, 2263-70	9.5	72
138	Screening of genes encoding junctional candidates in arrhythmogenic right ventricular cardiomyopathy/dysplasia. <i>Europace</i> , <b>2013</b> , 15, 1522-5	3.9	17
137	Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failure. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 1044-52	12.3	19
136	Championing cardiovascular health innovation in Europe. <i>Acta Cardiologica</i> , <b>2013</b> , 68, 650-5	0.9	1
135	Desmosomal cadherins are decreased in explanted arrhythmogenic right ventricular dysplasia/cardiomyopathy patient hearts. <i>PLoS ONE</i> , <b>2013</b> , 8, e75082	3.7	19
134	L'éducation thérapeutique du patient (ETP), une pièce maîtresse pour répondre aux nouveaux besoins de la médecine. <i>Bulletin De L'Académie Nationale De Médecine</i> , <b>2013</b> , 197, 1747-1781	0.1	3
133	Relationship of serum sodium concentration to mortality in a wide spectrum of heart failure patients with preserved and with reduced ejection fraction: an individual patient data meta-analysis (I): Meta-Analysis Global Group in Chronic heart failure (MAGGIC). <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 1139-46	12.3	74

132	Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial. <i>European Journal of Heart Failure</i> , <b>2012</b> , 14, 1401-9	12.3	21
131	From abstract to impact in cardiovascular research: factors predicting publication and citation. <i>European Heart Journal</i> , <b>2012</b> , 33, 3034-45	9.5	55
130	Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 59, 1938-45	15.1	183
129	Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). <i>European Heart Journal</i> , <b>2012</b> , 33, 2290-6	9.5	110
128	Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new Chronic Kidney Disease-Epidemiology Collaboration Group formula. <i>Circulation: Heart Failure</i> , <b>2012</b> , 5, 309-14	7.6	112
127	Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. <i>Circulation: Heart Failure</i> , <b>2012</b> , 5, 571-8	7.6	129
126	Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. <i>Circulation: Heart Failure</i> , <b>2012</b> , 5, 217-25	7.6	51
125	Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. <i>European Heart Journal</i> , <b>2012</b> , 33, 2813-20	9.5	97
124	The beat goes on: on the importance of heart rate in chronic heart failure. <i>European Heart Journal</i> , <b>2012</b> , 33, 1044-5	9.5	6
123	Clinical development of pharmacologic agents for acute heart failure syndromes: a proposal for a mechanistic translational phase. <i>American Heart Journal</i> , <b>2011</b> , 161, 224-32	4.9	32
122	A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. <i>European Heart Journal</i> , <b>2011</b> , 32, 1065-76	9.5	228
121	Clinical evaluation of cardiovascular devices: principles, problems, and proposals for European regulatory reform. Report of a policy conference of the European Society of Cardiology. <i>European Heart Journal</i> , <b>2011</b> , 32, 1673-86	9.5	53
120	Clinical trials in acute heart failure: simpler solutions to complex problems. Consensus document arising from a European Society of Cardiology cardiovascular round-table think tank on acute heart failure, 12 May 2009. <i>European Journal of Heart Failure</i> , <b>2011</b> , 13, 1253-60	12.3	27
119	Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). <i>Circulation: Heart Failure</i> , <b>2011</b> , 4, 27-35	7.6	184
118	Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. <i>Circulation: Heart Failure</i> , <b>2011</b> , 4, 561-8	7.6	80
117	Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. <i>Circulation: Heart Failure</i> , <b>2011</b> , 4, 569-77	7.6	173
116	Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. <i>Circulation</i> , <b>2011</b> , 124, 2491-501	16.7	322
115	Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. <i>Diabetes Care</i> , <b>2011</b> , 34, 1394-6	14.6	23



114	The future of clinical trials in secondary prevention after acute coronary syndromes. <i>European Heart Journal</i> , <b>2011</b> , 32, 1583-9	9.5	22
113	Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. <i>European Heart Journal</i> , <b>2011</b> , 32, 2395-404	9.5	141
112	Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. <i>European Heart Journal</i> , <b>2011</b> , 32, 2507-15	9.5	207
111	Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. <i>Circulation</i> , <b>2010</b> , 121, 1393-405	16.7	241
110	Myocarditis during acute schistosomiasis in two travelers. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2010</b> , 82, 365-7	3.2	11
109	The current and future management of acute heart failure syndromes. <i>European Heart Journal</i> , <b>2010</b> , 31, 784-93	9.5	81
108	Genetic association study identifies HSPB7 as a risk gene for idiopathic dilated cardiomyopathy. <i>PLoS Genetics</i> , <b>2010</b> , 6, e1001167	6	93
107	Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). <i>European Journal of Heart Failure</i> , <b>2010</b> , 12, 75-81	12.3	72
106	Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure. <i>European Journal of Heart Failure</i> , <b>2010</b> , 12, 239-48	12.3	173
105	Early identification of mutation carriers in familial hypertrophic cardiomyopathy by combined echocardiography and tissue Doppler imaging. <i>European Heart Journal</i> , <b>2010</b> , 31, 1599-607	9.5	30
104	Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. <i>European Heart Journal</i> , <b>2010</b> , 31, 824-31	9.5	176
103	Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure). <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 56, 1196-204	15.1	81
102	Long-term outcome after bare-metal or drug-eluting stenting for allograft coronary artery disease. <i>Journal of Heart and Lung Transplantation</i> , <b>2010</b> , 29, 316-22	5.8	12
101	Predictors of short term mortality in heart failure - insights from the Euro Heart Failure survey. <i>International Journal of Cardiology</i> , <b>2010</b> , 138, 63-9	3.2	45
100	Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. <i>Journal of Cardiac Failure</i> , <b>2010</b> , 16, 128-34	3.3	47
99	Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. <i>Lancet, The</i> , <b>2010</b> , 376, 886-94	40	615
98	Ivabradine and outcomes in chronic heart failure [Authors' reply]. <i>Lancet, The</i> , <b>2010</b> , 376, 2069-2070	40	3
97	Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. <i>Circulation: Heart Failure</i> , <b>2010</b> , 3, 314-25	7.6	120

96	Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. <i>Lancet, The</i> , <b>2010</b> , 376, 875-85	40	1646
95	Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. <i>European Heart Journal</i> , <b>2009</b> , 30, 3015-26	9.5	93
94	A new polymorphism in human calmodulin III gene promoter is a potential modifier gene for familial hypertrophic cardiomyopathy. <i>European Heart Journal</i> , <b>2009</b> , 30, 1648-55	9.5	28
93	Mutations in the ANKRD1 gene encoding CARP are responsible for human dilated cardiomyopathy. <i>European Heart Journal</i> , <b>2009</b> , 30, 2128-36	9.5	58
92	Improvement in the management of chronic heart failure since the publication of the updated guidelines of the European Society of Cardiology. The Impact-Reco Programme. <i>European Journal of Heart Failure</i> , <b>2009</b> , 11, 85-91	12.3	38
91	Years-needed-to-treat to add 1 year of life: a new metric to estimate treatment effects in randomized trials. <i>European Journal of Heart Failure</i> , <b>2009</b> , 11, 256-63	12.3	9
90	Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. <i>European Journal of Heart Failure</i> , <b>2009</b> , 11, 281-91	12.3	102
89	Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). <i>American Heart Journal</i> , <b>2009</b> , 157, 271-7	4.9	123
88	Consensus of the French Society of Gerontology and Geriatrics and the French Society of Cardiology for the management of coronary artery disease in older adults. <i>Archives of Cardiovascular Diseases</i> , <b>2009</b> , 102, 829-45	2.7	13
87	Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. <i>Lancet, The</i> , <b>2009</b> , 373, 2125-35	40	1059
86	Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. <i>Lancet, The</i> , <b>2009</b> , 374, 1840-8	40	408
85	Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. <i>European Heart Journal</i> , <b>2009</b> , 30, 478-86	9.5	198
84	The development of an international, common, prospective, cardiology database. Report of the joint G8 Cardio-Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO)--Societ� Fran�aise de Cardiologie (SFC) database committee. <i>Acute Cardiac Care</i> , <b>2009</b> , 11, 113-20		
83	Feasibility of outpatient coronary angiography with "ad hoc" angioplasty. <i>Archives of Cardiovascular Diseases</i> , <b>2008</b> , 101, 383-90	2.7	3
82	Irbesartan in patients with heart failure and preserved ejection fraction. <i>New England Journal of Medicine</i> , <b>2008</b> , 359, 2456-67	59.2	1307
81	A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. <i>European Heart Journal</i> , <b>2008</b> , 29, 816-24	9.5	109
80	New-onset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: results of the EuroHeart Failure Survey. <i>European Heart Journal</i> , <b>2008</b> , 29, 1618-24	9.5	104
79	Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. <i>European Journal of Heart Failure</i> , <b>2008</b> , 10, 149-56	12.3	144

78	Cardiologists' awareness and perceptions of guidelines for chronic heart failure. The ADDRESS your Heart survey. <i>European Journal of Heart Failure</i> , <b>2008</b> , 10, 1020-5	12.3	22
77	Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II. <i>European Journal of Heart Failure</i> , <b>2008</b> , 10, 140-8	12.3	110
76	Design of the heart failure endpoint evaluation of AII-antagonist losartan (HEAAL) study in patients intolerant to ACE-inhibitor. <i>European Journal of Heart Failure</i> , <b>2008</b> , 10, 899-906	12.3	12
75	Mutations in the Z-band protein myopalladin gene and idiopathic dilated cardiomyopathy. <i>Cardiovascular Research</i> , <b>2008</b> , 77, 118-25	9.9	78
74	State of the art: using natriuretic peptide levels in clinical practice. <i>European Journal of Heart Failure</i> , <b>2008</b> , 10, 824-39	12.3	529
73	Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. <i>Critical Care Medicine</i> , <b>2008</b> , 36, S129-39	1.4	188
72	Familial and sporadic hypertrophic myopathy: differences and similarities in a genotyped population. A long follow-up study. <i>Revista Portuguesa De Cardiologia</i> , <b>2008</b> , 27, 147-73	1	9
71	Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 49, 963-71	15.1	56
70	The safety of amiodarone in patients with heart failure. <i>Journal of Cardiac Failure</i> , <b>2007</b> , 13, 340-5	3.3	40
69	Effects of torcetrapib in patients at high risk for coronary events. <i>New England Journal of Medicine</i> , <b>2007</b> , 357, 2109-22	59.2	2323
68	Rosuvastatin in older patients with systolic heart failure. <i>New England Journal of Medicine</i> , <b>2007</b> , 357, 2248-61	59.2	1098
67	Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , <b>2007</b> , 9, 684-94	12.3	265
66	Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial. <i>European Journal of Heart Failure</i> , <b>2007</b> , 9, 795-801	12.3	60
65	Recall of lifestyle advice in patients recently hospitalised with heart failure: a EuroHeart Failure Survey analysis. <i>European Journal of Heart Failure</i> , <b>2007</b> , 9, 1095-103	12.3	47
64	International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: data from the EuroHeart Failure Survey. <i>European Journal of Heart Failure</i> , <b>2007</b> , 9, 292-9	12.3	54
63	Effect of carvedilol and metoprolol on the mode of death in patients with heart failure. <i>European Journal of Heart Failure</i> , <b>2007</b> , 9, 1128-35	12.3	30
62	Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. <i>European Journal of Heart Failure</i> , <b>2007</b> , 9, 901-9	12.3	71
61	Management of octogenarians hospitalized for heart failure in Euro Heart Failure Survey I. <i>European Heart Journal</i> , <b>2007</b> , 28, 1310-8	9.5	80

60	A familial form of conduction defect related to a mutation in the PRKAG2 gene. <i>Europace</i> , <b>2007</b> , 9, 597-600	11
59	Treatment of advanced chronic heart failure with normal left ventricular ejection fraction. Response to the letter by Dr. Martinez-Selles. <i>European Journal of Heart Failure</i> , <b>2007</b> , 9, 1224-1225	12.3 1
58	Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. <i>New England Journal of Medicine</i> , <b>2007</b> , 357, 28-38	59.2 618
57	The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. <i>European Heart Journal</i> , <b>2006</b> , 27, 1440-6	9.5 164
56	Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). <i>European Heart Journal</i> , <b>2006</b> , 27, 1216-22	9.5 249
55	Severe dilated cardiomyopathy and quadriceps myopathy due to lamin A/C gene mutation: a phenotypic study. <i>European Journal of Heart Failure</i> , <b>2006</b> , 8, 249-56	12.3 20
54	Molecular genetics in hypertrophic cardiomyopathy: towards individualized management of the disease. <i>Expert Review of Molecular Diagnostics</i> , <b>2006</b> , 6, 65-78	3.8 21
53	EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. <i>European Heart Journal</i> , <b>2006</b> , 27, 2725-36	9.5 825
52	A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET). <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 47, 1603-11	15.1 53
51	Lessons from the European heart survey. <i>Circulation</i> , <b>2006</b> , 113, f25-6	16.7 1
50	Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. <i>European Heart Journal</i> , <b>2005</b> , 26, 1303-8	9.5 486
49	Mutation screening in dilated cardiomyopathy: prominent role of the beta myosin heavy chain gene. <i>European Heart Journal</i> , <b>2005</b> , 26, 794-803	9.5 107
48	Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. <i>European Heart Journal</i> , <b>2005</b> , 26, 1653-9	9.5 263
47	Diagnostic accuracy of a 2D left ventricle hypertrophy score for familial hypertrophic cardiomyopathy. <i>European Heart Journal</i> , <b>2005</b> , 26, 1882-6	9.5 8
46	Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. <i>European Heart Journal</i> , <b>2005</b> , 26, 2706-13	9.5 143
45	Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. <i>European Heart Journal</i> , <b>2005</b> , 26, 2259-68	9.5 134
44	Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET. <i>American Heart Journal</i> , <b>2005</b> , 149, 370-6	4.9 61
43	The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. <i>Journal of Cardiac Failure</i> , <b>2005</b> , 11, 576-85	3.3 113

42	Comparative value of tissue Doppler imaging and m-mode color Doppler mitral flow propagation velocity for the evaluation of left ventricular filling pressure. <i>Chest</i> , <b>2005</b> , 128, 2544-50	5.3	33
41	Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial). <i>European Journal of Heart Failure</i> , <b>2005</b> , 7, 640-9	12.3	25
40	The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology: Guidelines for the Diagnosis and Treatment of Chronic Heart Failure: reply. <i>European Heart Journal</i> , <b>2005</b> , 26, 2473-2474	9.5	19
39	Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. <i>European Heart Journal</i> , <b>2005</b> , 26, 1115-40	9.5	1642
38	Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. <i>European Heart Journal</i> , <b>2005</b> , 26, 384-416	9.5	950
37	Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure. <i>European Heart Journal</i> , <b>2004</b> , 25, 1788-96	9.5	84
36	Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF Evaluation). <i>European Journal of Heart Failure</i> , <b>2004</b> , 6, 467-75	12.3	53
35	The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). <i>Cardiovascular Drugs and Therapy</i> , <b>2004</b> , 18, 57-66	3.9	104
34	A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET). <i>Cardiovascular Drugs and Therapy</i> , <b>2004</b> , 18, 139-52	3.9	9
33	Prevalence of anemia in patients with chronic heart failure and their clinical characteristics. <i>Journal of Cardiac Failure</i> , <b>2004</b> , 10, S1-4	3.3	51
32	Apical left ventricular aneurysm without atrio-ventricular block due to a lamin A/C gene mutation. <i>European Journal of Heart Failure</i> , <b>2003</b> , 5, 821-5	12.3	33
31	Functional consequences of an LMNA mutation associated with a new cardiac and non-cardiac phenotype. <i>Human Mutation</i> , <b>2003</b> , 21, 473-81	4.7	60
30	Polymorphisms of genes of the cardiac calcineurin pathway and cardiac hypertrophy. <i>European Journal of Human Genetics</i> , <b>2003</b> , 11, 659-64	5.3	20
29	Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure. <i>American Heart Journal</i> , <b>2003</b> , 146, 729-35	4.9	47
28	Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. <i>Circulation</i> , <b>2003</b> , 107, 2227-32	16.7	924
27	Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. <i>Lancet, The</i> , <b>2003</b> , 362, 7-13	40	1400
26	Relationships between the antihypertensive effects of bisoprolol and levels of plasma atrial natriuretic peptide in hypertensive patients. <i>Fundamental and Clinical Pharmacology</i> , <b>2002</b> , 16, 361-8	3.1	5
25	Genes and their polymorphisms in mono- and multifactorial cardiomyopathies: towards pharmacogenomics in heart failure. <i>Pharmacogenomics</i> , <b>2002</b> , 3, 367-78	2.6	9

24	Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. <i>European Journal of Heart Failure</i> , <b>2002</b> , 4, 321-9	12.3	61
23	Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects. <i>Journal of the American College of Cardiology</i> , <b>2002</b> , 39, 2034-41	15.1	27
22	Are angiotensin II receptor antagonists indicated in chronic heart failure?. <i>Heart Failure Monitor</i> , <b>2002</b> , 2, 85-7		1
21	Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure. <i>American Journal of Cardiology</i> , <b>2000</b> , 86, 417-21	3	43
20	Homozygotes for a R869G mutation in the beta -myosin heavy chain gene have a severe form of familial hypertrophic cardiomyopathy. <i>Journal of Molecular and Cellular Cardiology</i> , <b>2000</b> , 32, 1575-83	5.8	46
19	Lack of association between polymorphisms of eight candidate genes and idiopathic dilated cardiomyopathy: the CARDIGENE study. <i>Journal of the American College of Cardiology</i> , <b>2000</b> , 35, 29-35	15.1	56
18	Effects of prolonged propranolol treatment on left ventricular remodeling and oxidative stress after myocardial infarction in rats. <i>Journal of Cardiovascular Pharmacology</i> , <b>2000</b> , 35, 806-13	3.1	14
17	Characterization of a unique genetic variant in the beta1-adrenoceptor gene and evaluation of its role in idiopathic dilated cardiomyopathy. CARDIGENE Group. <i>Journal of Molecular and Cellular Cardiology</i> , <b>1999</b> , 31, 1025-32	5.8	97
16	Genetic aspects of heart failure. <i>European Journal of Heart Failure</i> , <b>1999</b> , 1, 121-6	12.3	10
15	Familial dilated cardiomyopathy: clinical features in French families. <i>European Journal of Heart Failure</i> , <b>1999</b> , 1, 353-61	12.3	16
14	Genotype-phenotype analysis in four families with mutations in beta-myosin heavy chain gene responsible for familial hypertrophic cardiomyopathy. <i>Human Mutation</i> , <b>1998</b> , 12, 385-92	4.7	29
13	Identification of two novel mutations in the ventricular regulatory myosin light chain gene (MYL2) associated with familial and classical forms of hypertrophic cardiomyopathy. <i>Journal of Molecular Medicine</i> , <b>1998</b> , 76, 208-14	5.5	100
12	Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. <i>Circulation</i> , <b>1998</b> , 97, 2230-6	16.7	196
11	The influence of the angiotensin I converting enzyme genotype in familial hypertrophic cardiomyopathy varies with the disease gene mutation. <i>Journal of Molecular and Cellular Cardiology</i> , <b>1997</b> , 29, 831-8	5.8	85
10	Correlation between left ventricular hypertrophy and GAA trinucleotide repeat length in Friedreich's ataxia. <i>Circulation</i> , <b>1997</b> , 95, 2247-9	16.7	64
9	Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in a genotyped adult population. <i>Circulation</i> , <b>1997</b> , 96, 214-9	16.7	100
8	Muscular blood flow response to submaximal leg exercise in normal subjects and in patients with heart failure. <i>Journal of Applied Physiology</i> , <b>1996</b> , 81, 2571-9	3.7	32
7	Codon 102 of the cardiac troponin T gene is a putative hot spot for mutations in familial hypertrophic cardiomyopathy. <i>Circulation</i> , <b>1996</b> , 94, 3069-73	16.7	76

6	Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy. <i>Nature Genetics</i> , <b>1995</b> , 11, 438-40	36.3	363
5	Doppler echocardiography in familial hypertrophic cardiomyopathy: the French Cooperative Study. <i>Echocardiography</i> , <b>1995</b> , 12, 235-41	1.5	12
4	Molecular basis of familial cardiomyopathies. <i>Circulation</i> , <b>1995</b> , 91, 532-40	16.7	114
3	Exclusion of HRAS from long QT locus. <i>Nature Genetics</i> , <b>1994</b> , 8, 113-4	36.3	20
2	Identification of a mutation near a functional site of the beta cardiac myosin heavy chain gene in a family with hypertrophic cardiomyopathy. <i>Journal of Molecular and Cellular Cardiology</i> , <b>1994</b> , 26, 1241-7	5.8	14
1	Genetics of familial hypertrophic cardiomyopathy Results and strategies. <i>Trends in Cardiovascular Medicine</i> , <b>1993</b> , 3, 115-8	6.9	5